ATAD1 and malaria: Indeed, a recent phase 1 clinical trial with full-length MSP1 (SumayaVac1) was safe and induced high titers of strain-transcending antibodies with complement fixation and ADRB activity in malaria-naïve adults (Blank et al, 2020).